Remoxipride

Jump to: navigation, search
Remoxipride
Remoxipride Structural Formulae.png
Clinical data
Trade namesRoxiam
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • Withdrawn
Pharmacokinetic data
Bioavailability96%[1]
Protein binding89-98%
MetabolismHepatic[1]
Elimination half-life4-7 hours[1]
ExcretionRenal[1]
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H23BrN2O3
Molar mass371.27 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Remoxipride

Articles

Most recent articles on Remoxipride

Most cited articles on Remoxipride

Review articles on Remoxipride

Articles on Remoxipride in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Remoxipride

Images of Remoxipride

Photos of Remoxipride

Podcasts & MP3s on Remoxipride

Videos on Remoxipride

Evidence Based Medicine

Cochrane Collaboration on Remoxipride

Bandolier on Remoxipride

TRIP on Remoxipride

Clinical Trials

Ongoing Trials on Remoxipride at Clinical Trials.gov

Trial results on Remoxipride

Clinical Trials on Remoxipride at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Remoxipride

NICE Guidance on Remoxipride

NHS PRODIGY Guidance

FDA on Remoxipride

CDC on Remoxipride

Books

Books on Remoxipride

News

Remoxipride in the news

Be alerted to news on Remoxipride

News trends on Remoxipride

Commentary

Blogs on Remoxipride

Definitions

Definitions of Remoxipride

Patient Resources / Community

Patient resources on Remoxipride

Discussion groups on Remoxipride

Patient Handouts on Remoxipride

Directions to Hospitals Treating Remoxipride

Risk calculators and risk factors for Remoxipride

Healthcare Provider Resources

Symptoms of Remoxipride

Causes & Risk Factors for Remoxipride

Diagnostic studies for Remoxipride

Treatment of Remoxipride

Continuing Medical Education (CME)

CME Programs on Remoxipride

International

Remoxipride en Espanol

Remoxipride en Francais

Business

Remoxipride in the Marketplace

Patents on Remoxipride

Experimental / Informatics

List of terms related to Remoxipride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients).[2] It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993.[2] Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.[3]

Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed.[4] There was some interest in its use in the treatment of treatment-resistant schizophrenia.[5][6]

See also

References

  1. 1.0 1.1 1.2 1.3 Grind, M; Nilsson, MI; Nilsson, L; Oxenstierna, G; Sedvall, G; Wahlén, A (1989). "Remoxipride - a new potential antipsychotic compound: tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers". Psychopharmacology. 98 (3): 304-309. doi:10.1007/bf00451679. PMID 2568653.
  2. 2.0 2.1 José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
  3. Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K (1990). "Biochemical pharmacology of the atypical neuroleptic remoxipride". Acta Psychiatrica Scandinavica. Supplementum. 358: 27–36. PMID 1978484.
  4. Alexander, MS; Chakravarti, SK; Sundararajan, K; Mullin, JM; Shaw, SH; Blomqvist, M; Lockett, CM (January 1993). "Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia". Journal of Psychopharmacology. 7 (3): 276-82. doi:10.1177/026988119300700307. PMID 22290842.
  5. Conley, R; Dixon, L; An Nguyen, R; Taminga, C; Hain, R (April 1993). "Remoxipride therapy in treatment resistant schizophrenia". Schizophrenia Research. 9 (2–3): 235-236. doi:10.1016/0920-9964(93)90521-J.
  6. Conley, R; Dixon, L; An Nguyen, R; Taminga, C; Raymond, R (April 1993). "Remoxipride therapy in poorly responsive schizophrenics". Schizophrenia Research. 4 (3): 316. doi:10.1016/0920-9964(91)90208-9.

External links


Template:Sigmaergics


Linked-in.jpg